this post was submitted on 29 Apr 2024
35 points (97.3% liked)

Public Health

378 readers
1 users here now

For issues concerning:

🩺 This community has a broader scope so please feel free to discuss. When it may not be clear, leave a comment talking about why something is important.

Related Communities

See the pinned post in the Medical Community Hub for links and descriptions. link ([email protected])

Rules

Given the inherent intersection that these topics have with politics, we encourage thoughtful discussions while also adhering to the mander.xyz instance guidelines.

Try to focus on the scientific aspects and refrain from making overly partisan or inflammatory content

Our aim is to foster a respectful environment where we can delve into the scientific foundations of these topics. Thank you!

founded 1 year ago
MODERATORS
[email protected]
[email protected]
35
Human papillomavirus vaccination in Ethiopia protects over 6.3 million girls from cervical cancer (www.afro.who.int)
submitted 6 months ago by [email protected] to c/[email protected]
3 comments fedilink hide all child comments
you are viewing a single comment's thread
view the rest of the comments
[–] [email protected] 4 points 6 months ago* (last edited 6 months ago)

This is a community for public health, and the article is about a vaccination campaign that just happened in that country. It's not relevant for everyone, but it can be relevant for people working in the field.

Saba is one of the 1.5 million 14-year-old girls who were vaccinated in early March 2024, as part of a four-day nationwide vaccination campaign. The HPV vaccine is being administered using a campaign mode by availing vaccination for four consecutive days at fixed vaccination posts and temporary fixed vaccination posts at schools where most of the target age group, 14-year-age girls, are easily found.

Based on the MoH decision and the country’s National Immunization Technical Advisory Groups, the two-dose schedule used over the past five years was switched to a single-dose schedule for the primary target group, girls aged 14 years. The decision was based on the evidence which indicated that a single-dose schedule provides solid protection with a comparable efficacy to the two or three-dose schedules. This evidence has also been evaluated and recommended by the WHO Strategic Advisory Group of Experts on Immunization (SAGE) in 2022.

I'm open to suggestions if you want to see other types of updates in this community (ex. the research articles).

If the problem is that you don't like seeing posts from [email protected] in your feed, you can block the community